论文部分内容阅读
目的:观察吉西他滨(泽菲)联合卡铂治疗Ⅲb或Ⅳ期初治非小细胞肺癌(NSCLC)的疗效和毒副作用。方法:初治的Ⅲb或Ⅳ期NSCLC46例,采用吉西他滨(泽菲)1200mg/m2,d1、d8,静滴;卡铂AUC=5,d1,静滴,21天为1个周期。结果:46例患者中,无CR病例,PR21例,SD20例,PD5例,客观有效率(CR+PR)为45.65%,中位生存期11.8个月,1年生存率35%(16/46),中位肿瘤进展时间7个月。毒副作用主要为中性粒细胞和血小板减少。结论:吉西他滨联合卡铂一线治疗晚期NSCLC有效率较高,有生存优势,毒副作用可耐受。
Objective: To observe the curative effect and side effects of gemcitabine (Zephytam) combined with carboplatin in the treatment of stage Ⅲb or Ⅳ primary non-small cell lung cancer (NSCLC). Methods: Forty-six patients with newly diagnosed stage Ⅲb or Ⅳ NSCLC were treated with gemcitabine 1200mg / m2, d1 and d8 for intravenous infusion. Carboplatin AUC = 5, d1 and intravenous drip for 21 days for one cycle. Results: There were no CR cases, PR21 cases, SD20 cases and PD5 cases in 46 patients. The objective effective rate (CR + PR) was 45.65%, the median survival time was 11.8 months and the 1-year survival rate was 35% (16/46 ), The median tumor progression time of 7 months. The main side effects of neutrophils and thrombocytopenia. Conclusion: Gemcitabine combined with carboplatin first-line treatment of advanced NSCLC has a high efficiency, survival advantage, toxic side effects can be tolerated.